In this multipart special report, BioWorld explores the concept of extending lifespan, which is surprisingly well-validated by basic research. The team examined the latest science, the key biological drivers that can be targeted pharmacologically and the companies developing these potential “Fountain of Youth” candidate drugs.
Japan’s Ministry of Health, Labor and Welfare has cleared Japan Tissue Engineering Co. Ltd.’s (J-Tec) autologous cultured cartilage, called Jacc, after a seven-year re-examination period.
Precision Autoimmune Therapeutics Co. Ltd. has raised ¥140 million (US$21 million) in its first financing round to speed up its pipeline development and improve its drug development platform. Emerging Technology Partners LLC, Redhill Capital and CASI Pharmaceuticals Inc. participated in the round.
Australia’s Therapeutic Goods Administration (TGA) should better align its definitions and classifications for gene, cell and tissue frameworks with international regulators, stakeholders said.
China’s NMPA gave the green light to Simcere Pharmaceutical Group Ltd. for Cosela (injectable trilaciclib hydrochloride) as a treatment to decrease the risk of chemotherapy-induced myelosuppression. It is intended for adult patients with extensive-stage small-cell lung cancer (ES-SCLC), before they undergo a platinum/etoposide-containing regimen.
Clinical updates from Asia, including trial initiations, enrollment status and data readouts and publications: Abbisko, Arctic Vision, Ascletis, Humanigen, Hutchmed, Inmagene, JW, Moleculin, Obi, Sunho, Takeda, Veru.
Regulatory snapshots, including drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations in Asia-Pacific: Ascletis, Biogen, Biontech, Coherus, Eisai, Innocare, Junshi, Kazia, MGC, Novavax, Nrx, Olix, Pfizer, Puma, Sensorion, Takeda.
RSS
